Tags

Type your tag names separated by a space and hit enter

Coenzyme Q10 supplementation and diastolic heart functions in hemodialysis patients: a randomized double-blind placebo-controlled trial.

Abstract

Coenzyme Q10 (CoQ10) supplementation has been shown to improve diastolic heart function in various patient cohorts. Systolic and diastolic dysfunctions are common in patients with end-stage renal disease. Favorable effects of CoQ10 on cardiac functions are yet to be seen in hemodialysis patients. We aimed to evaluate effect of CoQ10 supplementation on diastolic function in a cohort of maintenance hemodialysis patients. This was a prospective, double-blind, placebo-controlled, crossover study in which all patients received placebo and oral CoQ10 200 mg/d during the 8 weeks in each phase, with a 4-week washout period. Participants underwent conventional and tissue Doppler echocardiography before and after each study phase. Parameters characterizing left ventricle diastolic function and other standard echocardiographic measurements were recorded. Twenty-eight patients were randomized, but 22 patients completed study protocol. Intraventricular septum (IVS) thickness and left ventricle mass were significantly decreased in CoQ10 group (P = 0.03 and P = 0.01, respectively). Myocardial peak systolic and early diastolic velocities derived from IVS were significantly increased (P = 0.048 and P = 0.04, respectively). Isovolumetric relaxation time and E/Em ratio calculated for IVS also significantly reduced in CoQ10 group (p = 0.02 and p = 0.04, respectively). There was no significant difference in any of the studied echocardiographic parameters in placebo group. The results of this study showed that CoQ10 supplementation did not significantly improved diastolic heart functions compared with placebo in maintenance hemodialysis patients.

Links

  • Publisher Full Text
  • Authors+Show Affiliations

    ,

    Nephrology Unit, Department of Internal Medicine, Meram School of Medicine, Selcuk University, Konya, Turkey.

    , , , , , , , , ,

    Source

    MeSH

    Cohort Studies
    Cross-Over Studies
    Diastole
    Double-Blind Method
    Echocardiography, Doppler
    Female
    Heart
    Humans
    Kidney Failure, Chronic
    Male
    Middle Aged
    Placebos
    Prospective Studies
    Renal Dialysis
    Ubiquinone

    Pub Type(s)

    Journal Article
    Randomized Controlled Trial

    Language

    eng

    PubMed ID

    23360359

    Citation

    Turk, Suleyman, et al. "Coenzyme Q10 Supplementation and Diastolic Heart Functions in Hemodialysis Patients: a Randomized Double-blind Placebo-controlled Trial." Hemodialysis International. International Symposium On Home Hemodialysis, vol. 17, no. 3, 2013, pp. 374-81.
    Turk S, Baki A, Solak Y, et al. Coenzyme Q10 supplementation and diastolic heart functions in hemodialysis patients: a randomized double-blind placebo-controlled trial. Hemodial Int. 2013;17(3):374-81.
    Turk, S., Baki, A., Solak, Y., Kayrak, M., Atalay, H., Gaipov, A., ... Gokbel, H. (2013). Coenzyme Q10 supplementation and diastolic heart functions in hemodialysis patients: a randomized double-blind placebo-controlled trial. Hemodialysis International. International Symposium On Home Hemodialysis, 17(3), pp. 374-81. doi:10.1111/hdi.12022.
    Turk S, et al. Coenzyme Q10 Supplementation and Diastolic Heart Functions in Hemodialysis Patients: a Randomized Double-blind Placebo-controlled Trial. Hemodial Int. 2013;17(3):374-81. PubMed PMID: 23360359.
    * Article titles in AMA citation format should be in sentence-case
    TY - JOUR T1 - Coenzyme Q10 supplementation and diastolic heart functions in hemodialysis patients: a randomized double-blind placebo-controlled trial. AU - Turk,Suleyman, AU - Baki,Aysegul, AU - Solak,Yalcin, AU - Kayrak,Mehmet, AU - Atalay,Huseyin, AU - Gaipov,Abduzhappar, AU - Aribas,Alpay, AU - Akilli,Hakan, AU - Biyik,Zeynep, AU - Okudan,Nilsel, AU - Gokbel,Hakki, Y1 - 2013/01/29/ PY - 2012/08/06/received PY - 2012/12/17/revised PY - 2013/1/31/entrez PY - 2013/1/31/pubmed PY - 2014/5/7/medline SP - 374 EP - 81 JF - Hemodialysis international. International Symposium on Home Hemodialysis JO - Hemodial Int VL - 17 IS - 3 N2 - Coenzyme Q10 (CoQ10) supplementation has been shown to improve diastolic heart function in various patient cohorts. Systolic and diastolic dysfunctions are common in patients with end-stage renal disease. Favorable effects of CoQ10 on cardiac functions are yet to be seen in hemodialysis patients. We aimed to evaluate effect of CoQ10 supplementation on diastolic function in a cohort of maintenance hemodialysis patients. This was a prospective, double-blind, placebo-controlled, crossover study in which all patients received placebo and oral CoQ10 200 mg/d during the 8 weeks in each phase, with a 4-week washout period. Participants underwent conventional and tissue Doppler echocardiography before and after each study phase. Parameters characterizing left ventricle diastolic function and other standard echocardiographic measurements were recorded. Twenty-eight patients were randomized, but 22 patients completed study protocol. Intraventricular septum (IVS) thickness and left ventricle mass were significantly decreased in CoQ10 group (P = 0.03 and P = 0.01, respectively). Myocardial peak systolic and early diastolic velocities derived from IVS were significantly increased (P = 0.048 and P = 0.04, respectively). Isovolumetric relaxation time and E/Em ratio calculated for IVS also significantly reduced in CoQ10 group (p = 0.02 and p = 0.04, respectively). There was no significant difference in any of the studied echocardiographic parameters in placebo group. The results of this study showed that CoQ10 supplementation did not significantly improved diastolic heart functions compared with placebo in maintenance hemodialysis patients. SN - 1542-4758 UR - https://www.unboundmedicine.com/medline/citation/23360359/Coenzyme_Q10_supplementation_and_diastolic_heart_functions_in_hemodialysis_patients:_a_randomized_double_blind_placebo_controlled_trial_ L2 - https://doi.org/10.1111/hdi.12022 DB - PRIME DP - Unbound Medicine ER -